KR20160098568A - COMPOSITION COMPRISING EXTRACT OF Quamoclit angulata HAVING ANTI-INFLAMMATORY ACTIVITY - Google Patents
COMPOSITION COMPRISING EXTRACT OF Quamoclit angulata HAVING ANTI-INFLAMMATORY ACTIVITY Download PDFInfo
- Publication number
- KR20160098568A KR20160098568A KR1020150019380A KR20150019380A KR20160098568A KR 20160098568 A KR20160098568 A KR 20160098568A KR 1020150019380 A KR1020150019380 A KR 1020150019380A KR 20150019380 A KR20150019380 A KR 20150019380A KR 20160098568 A KR20160098568 A KR 20160098568A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- inflammatory
- leaf
- composition
- quamoclit angulata
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 36
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 21
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 20
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 244000163122 Curcuma domestica Species 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 235000003373 curcuma longa Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001245662 Eragrostis rigidior Species 0.000 description 4
- -1 for example Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 3
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- 101100190284 Arabidopsis thaliana PHE2 gene Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZCUQOPGIJRGJDA-UHFFFAOYSA-N 1-naphthalen-1-ylethane-1,2-diamine Chemical compound C1=CC=C2C(C(N)CN)=CC=CC2=C1 ZCUQOPGIJRGJDA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000007108 Fuchsia magellanica Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012747 synergistic agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
The present invention relates to an antiinflammatory pharmaceutical composition and a food composition containing a Quamoclit angulata extract.
Inflammation is one of the defenses of the body against physical stimuli, chemical stimuli, bacterial infections, etc. It is one of the mechanisms to remove external substances and regenerate damaged areas. Once an inflammation-related stimulus is applied, vasoactive substances such as histamine, serotonine, bradykinin, prostaglandin, hydroxyeicosatetraenoic acid (HETE), leukotriene And the vascular permeability is increased to cause inflammation.
Monocytes are transformed into macrophages that are activated by bacterial infection and act as phagocytic cells. Macrophages induce inflammation by secretion of NO, prostaglandin E2, and proinflammatory cytokines, and regulatory cells important in both inflammation and immune response In order for macrophages to function in this way, they must undergo an activation process.
LPS (lipopolysaccharide), one of the cell wall components of Gram-negative bacteria and well known as endotoxin, is the most well-known external factor involved in macrophage activation. Particularly, in monocytes and macrophages such as RAW 264.7 cells, proinflammatory cytokines such as TNF-α, IL-6 (interleukin-6) and IL-1β (interleukin- -inflammatory cytokine secreted by LPS (lipopolysaccharide) in the inflamed area.
When LPS stimulates macrophages, nitric oxide (NO) is produced in the process of converting L-arginine into L-citrulline by an enzyme called iNOS (inducible nitric oxide synthase) Phagocytes produce NO.
In mammals, NO is synthesized by three kinds of NO synthase (NOS): nNOS (neuronal NOS), eNOS (endothelial NOS) and iNOS (inducible NOS). Among these, NO produced by nNOS and eNOS is produced for normal biological function, and the concentration in tissues is kept low to a certain level. However, the amount of NO produced by iNOS is excessively high, and it is harmful to living organisms such as pathological vasodilation, cytotoxicity and tissue damage. In addition, prostaglandin E2 (PGE2), an inflammatory factor, stimulates phospholipid, which is a constituent of cell membrane, stimulated by LPS, and arachidonic acid liberated by an enzyme called phospholipase A2 causes catalytic action of an enzyme called COXs (cyclooxygenase) And is induced to induce an inflammatory reaction.
COX is classified as COX-1 and COX-2. COX-1 acts on normal biological functions such as platelet formation, gastric wall protection and maintenance of renal function in the body. COX-2 synthesizes PHE2 as an inflammatory mediator. PHE2 is known to be deeply involved in the development of cancer, such as promoting inflammation (pain, fever, etc.), immune response, and angiogenesis. Inhibition of iNOS is mostly due to its mechanism of action being linked to inhibitors of COXs. Therefore, iNOS inhibition materials that are relatively easy to search are discovered and developed as anti-inflammatory materials.
On the other hand, non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, have anti-inflammatory, antipyretic and analgesic effects. However, the long-term use of these drugs can sometimes lead to serious side effects. For example, secondary anemia due to gastrointestinal peptic ulcer bleeding, platelet function suppression, inhibition of induction of labor, side effects to the kidney, liver damage, hypersensitivity.
In order to overcome the side effects of these drugs, natural products such as plants are more preferable as a safer material. In this regard, researches are being actively carried out to find and use the anti-inflammatory materials in natural products.
Quamoclit angulata , an annual plant of Convolvulaceae , is a native plant of tropical Americas and cultivated for ornamental purposes. No studies have been reported on the anti-inflammatory effect of this plant.
It is an object of the present invention to provide a composition containing a plant extract having excellent antiinflammatory activity, and it has been confirmed that a component extracted from Quamoclit angulata has an inhibitory effect on inflammatory factor expression, And to provide a food composition.
In order to achieve the above object, the pharmaceutical composition of anti-inflammatory activity according to one embodiment of the present invention contains Quamoclit angulata extract.
The above-mentioned Curly Leaf Root Extract may be one selected from the group consisting of alcohols having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water, and mixtures thereof, and may be extracted by cold precipitation.
The above-mentioned Curly Leaf Root Extract is obtained by extracting 1 to 5 times by adding a solvent having a dry weight of 3 to 20 times by weight to a dry powder of Curly Leaf Leaf, and extracting it at an extraction temperature of 20 to 120 캜 for 30 minutes to 10 days An extract or a powder from which the solvent has been removed from the extract.
The food composition according to another embodiment of the present invention contains an extract of Quamoclit angulata and has an anti-inflammatory function. The food composition has antibacterial activity and can be used as a food composition in the form of a health functional food, a nutritional supplement, a health food, or a food additive.
Hereinafter, the present invention will be described in more detail.
The anti-inflammatory composition according to one embodiment of the present invention contains a Quamoclit angulata extract.
The above-mentioned Curly Leaf Root Extract may be obtained by extracting Curd Leaf Leaf, drying and crushing and pulverizing. The above-mentioned dried and pulverized curd leaves may be leaves, stems, roots, flowers, fruits, mixtures or outbreaks of the curd leaf, and the drying may be carried out in such a range that the useful components in the collected curd leaves are not destroyed It can be carried out by a known method, for example, by a method of natural drying in shade. In addition, it is preferable that the above-mentioned crushing is carried out after crushing to such an extent that the useful components of the curd leaf can be sufficiently extracted in the subsequent extraction process and pulverized. The drying and crushing steps may be carried out in reverse order or repeatedly as required.
The extraction may be carried out by, for example, hot water extraction, cold extraction, warming extraction, reflux cooling extraction, ultrasonic extraction, or the like, preferably by a cold extraction method.
The extraction is carried out using a solvent, which may be an alcohol of 1 to 5 carbon atoms, hexane, chloroform, alcohol, water and mixtures thereof, preferably water, methanol, ethanol, .
The extraction is carried out at a temperature of 20 to 100 ° C, preferably 20 to 70 ° C, for 30 to 10 minutes, preferably 3 to 20 times, preferably 3 to 10 times, Day, or 1 to 2 days of extraction time, and it is preferable to use a method of preparing a curd leaf foliage comprising 1 to 5 times, preferably 2 to 3 times, Followed by continuous extraction to obtain a liquid-phase extract.
The above-mentioned liquid-phase curly leaf extract can be subjected to a process such as concentration filtration or drying after separating it from the foliage of the curly leaf by a method such as reduced pressure filtration. For example, the above-mentioned liquid phase curly leaf extract can be concentrated in a vacuum rotary condenser at 20 to 100 ° C, preferably at 40 to 70 ° C, and the liquid phase curd leaf extract is dried to obtain powdered You can also obtain a Curly Leaf Root Extract. The thus-concentrated or powdered Curly Leaf Root Extract can be used as needed in water, alcohol or a mixed solvent thereof.
In addition, the above-mentioned liquid round-rooted hwangchongcho extract, its concentrate or its powder may be an extract obtained by fractionation with nucleic acid or ethyl acetate or fractionation of the fraction.
The above-mentioned Curly Leaf Root Leaf Extract inhibits the expression of iNOS, an inflammation mediator, and inhibits the expression of NO produced by this enzyme, thereby providing a pharmaceutical composition of anti-inflammatory activity containing components useful for prevention and treatment of inflammation-related diseases And can be used as a pharmaceutical composition for the prevention or treatment of inflammatory diseases, and provides a pharmaceutical composition for preventing or treating inflammation caused by infection from external bacteria.
The anti-inflammatory composition may further comprise additional components and may further comprise at least one of, for example, a carrier, excipient, and diluent, for example, lactose, dextrose, sucrose, sorbitol, But are not limited to, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate Tartrate, magnesium stearate, and mineral oil.
The antiinflammatory composition may have various formulations and may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, external preparations such as syrups and aerosols, have. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used, and the preparations for non-oral administration include sterilized aqueous solutions, Emulsions, freeze-dried preparations, suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
The preferred dosage of the anti-inflammatory composition may be appropriately selected depending on the condition and body weight of the patient, the degree of disease, the form of the drug, the route of administration and the period of time. However, for the desired anti-inflammatory effect, the extract or the compound of the present invention can be administered in an amount of 0.01 to 500 mg / kg per day, preferably 0.1 to 200 mg / kg per day, divided once to several times per day. The dose of the compound may also be increased or decreased depending on the route of administration, degree of disease, sex, weight, age, and the like.
The food composition according to another embodiment of the present invention contains an extract of Quamoclit angulata and has an anti-inflammatory function and is used as a food composition in the form of a health functional food, a nutritional supplement, a health food, or a food additive Can be utilized.
Food compositions of this type can be prepared in a variety of forms according to conventional methods. For example, the health food may be prepared by lyophilization, granulation, encapsulation and pulverization so as to be prepared in the form of tea, juice and drink, and then drinking the same. In addition, it can be prepared in the form of a composition by mixing together the above-mentioned Curly Leaf Root Extract and a known active ingredient known to have anti-inflammatory effect. Functional foods also include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods such as canned fruits, jars, jam, maare marlade, fish, meat and processed foods (Eg butter, cheeses, etc.), edible vegetable oils (eg, sourdoughs, etc.), breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, , Margarine, vegetable protein, retort food, frozen food, various kinds of seasoning (e.g., soybean paste, soy sauce, sauce, etc.). The preferred content of the Curly Leaf-Root Extract in the food composition is not particularly limited, but is preferably 0.01 to 50% by weight in the finally prepared food.
The anti-inflammatory composition and the food composition of the present invention contain Quamoclit angulata extract and have an inflammatory factor expression inhibiting activity and are useful as a pharmaceutical composition or a functional food composition.
FIG. 1 shows the results of evaluation of the amount of NO produced from the samples treated with the extract of Curcuma longa root, prepared in Example 1 of the present invention.
FIG. 2 shows the results of evaluating iNOS activity by samples obtained from the samples treated with the extract of Curly Leaf Root Prepared in Example 1 of the present invention, and evaluating the iNOS inhibitory effect of the extracts according to their concentrations.
Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
Example 1: Curly leaf foliage ( Quamoclit angulata ) Preparation of extract
The outposts of Quamoclit angulate, which is native to Korea, were collected, dried in a well-ventilated shade, and then dried to a size of 20 mesh or less.
1 g of ethanol was added to 100 g of the dry powder of the mouth, and the mixture was cooled at room temperature for 7 days at room temperature for 7 days. The mixture was extracted three times repeatedly and filtered through a filter paper (Wattsman, USA) to obtain a filtered extract. The filtrate was subjected to removal of ethanol at 40 ° C by using a vacuum rotary condenser to obtain 12 to 20 g of a round-mouth yuchongcho extract residue. 10 mg of the sample was used as a sample for the detection of the anti-inflammatory activity.
Example 2: Anti-inflammatory activity of the extract of Curcuma pseudo-acacia var.
The anti - inflammatory effect of the extract of Curcuma longa root was confirmed by measuring the amount of NO and using iNOS (inducible nitric oxide synthase) assay.
RAW 264.7 cells were inoculated into a 24-well plate at a density of 10 x 10 cells / well using DMEM medium and cultured for 12 hours. The RAW 264.7 cells were cultured in the same manner as in Example 1, / ml and LPS (1? / ml) at the same time, and cultured for 24 hours. From the cultured samples, the amount of NO 2 - present in the cell culture was measured using a Griess reagent, and the amount of NO produced and iNOS activity were measured. Specifically, 500 μl of the cell culture supernatant of the above cultured samples and 50 μl of a grease reagent (2.5% sulfanilamide, 0.25% naphthylethylenediamine dissolved in 10% phosphoric acid) were mixed and reacted on a 24-well plate for 10 minutes Absorbance was measured at 540 nm using an ELISA reader. The standard concentration curve was obtained by serial dilution of DMSO, and the amount of produced NO and the activity of iNOS were evaluated. The results are shown in FIGS. 1 and 2. As a positive control, aspirin was applied.
Referring to FIG. 1, it can be confirmed that the extract of Curcuma pseudo-acacia L. leaves effectively inhibited the production of NO in RAW 264.7 c cells induced by LPS. As a result, It is also confirmed that it is dependent.
NO is synthesized from L-arginine by nitric oxide synthase (NOS). Under pathologic conditions, increased NO promotes the development of inflammation, which is synthesized by iNOS, a synergistic agent with other inflammatory mediators. In addition, iNOS is strongly stimulated by exposure to inflammatory cytokines and bacterial endotoxins. Therefore, a substance capable of reducing NO production by iNOS can be utilized as an anti-inflammatory agent.
In addition, referring to FIG. 2, it was confirmed that the extract of R. leucocyte showed an inhibitory effect on iNOS in RAW 264.7 cells induced by LPS, and that it was dose-dependent overall, except for 20 ug / ml.
NO produced by activated iNOS in inflammatory conditions has deleterious effects on the organism such as pathological vasodilation, cytotoxicity, and tissue damage. The effect of LPS treatment on RAW 264.7 on the NO production of the leaf currant leaf showed a strong inhibitory effect. The positive control (Aspirin, 100 μg / ml) effectively inhibited the activity of iNOS.
The above-mentioned Curcuma longa root extract showed a concentration-dependent reduction of LPS-induced NOS production, and it was confirmed that the Curcuma longa root extract showed a strong inhibitory effect on iNOS protein expression in RAW 264.7 cells induced by LPS .
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.
Claims (4)
Wherein the curd leaf is at least one selected from the group consisting of alcohols having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water, and mixtures thereof, and is extracted by cold precipitation.
The above-mentioned Curly Leaf Root Extract is obtained by extracting 1 to 5 times by adding a solvent having a dry weight of 3 to 20 times by weight to a dry powder of Curly Leaf Leaf, and extracting it at an extraction temperature of 20 to 120 캜 for 30 minutes to 10 days An extract or a powder from which the solvent is removed from the extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150019380A KR20160098568A (en) | 2015-02-09 | 2015-02-09 | COMPOSITION COMPRISING EXTRACT OF Quamoclit angulata HAVING ANTI-INFLAMMATORY ACTIVITY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150019380A KR20160098568A (en) | 2015-02-09 | 2015-02-09 | COMPOSITION COMPRISING EXTRACT OF Quamoclit angulata HAVING ANTI-INFLAMMATORY ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160098568A true KR20160098568A (en) | 2016-08-19 |
Family
ID=56874691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150019380A KR20160098568A (en) | 2015-02-09 | 2015-02-09 | COMPOSITION COMPRISING EXTRACT OF Quamoclit angulata HAVING ANTI-INFLAMMATORY ACTIVITY |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160098568A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110095835A (en) | 2010-02-19 | 2011-08-25 | 한국생명공학연구원 | Pharmaceutical compositon for treating diabetes containing extract of quamoclit angulata |
-
2015
- 2015-02-09 KR KR1020150019380A patent/KR20160098568A/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110095835A (en) | 2010-02-19 | 2011-08-25 | 한국생명공학연구원 | Pharmaceutical compositon for treating diabetes containing extract of quamoclit angulata |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101751398B1 (en) | Composition comprising Angelica gigas Nakai, Cornus officinalis, Cervi Parvum Cornu, Red ginseng, Rehmanniae Radix Preparata, Aquilaria agallocha Roxburgh and Honey for anti-inflammation | |
| JP3768795B2 (en) | Xanthine oxidase inhibitor | |
| JP4950682B2 (en) | Propolis extract | |
| KR20160098571A (en) | COMPOSITION COMPRISING EXTRACT OF Carex scabrifolia Steud HAVING ANTI-INFLAMMATORY AND ANTI-OXIDANT ACTIVITY | |
| KR102086854B1 (en) | Anti-oxidant or anti-inflammatory cosmetic compositions containing the plants extract of Cyperaceae | |
| JP2006036787A (en) | Xanthine oxidase inhibitor | |
| KR101317668B1 (en) | Pharmaceutical composition for treating and preventing arthritis comprising stauntonia hexaphylla leaf extract | |
| KR101687770B1 (en) | COMPOSITION COMPRISING EXTRACT OF Eriocaulon decemflorum HAVING ANTI-INFLAMMATORY AND ANTI-OXIDANT ACTIVITY | |
| KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
| KR101879685B1 (en) | Composition for anti-inflammation with nipa fruticans wurmb | |
| JP4537024B2 (en) | Inflammatory disease preventive / therapeutic agent | |
| KR101935689B1 (en) | Composition comprising mixture extract of jujube, licorice and platycodon for enhancing immune response | |
| KR20160141463A (en) | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis | |
| KR101193558B1 (en) | An anti-inflammatory pharmaceutical composition comprising of extracts as an effective component from Laminaria japonica | |
| KR101831438B1 (en) | Composition comprising uldavioside A compound for preventing or treating of inflammatory disease | |
| KR101790657B1 (en) | Extraction of polysaccharides from pine nut cake and composition comprising pine nut extract for enhancement of immunity | |
| KR101747696B1 (en) | A composition comprising compounds isolated from Echinochloa utilis for preventing or treating inflammatory disease | |
| JP4371431B2 (en) | Antiallergic composition | |
| KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| KR20160098567A (en) | Composition comprising extract of rhododendron micranthum having anti-oxidant and anti-inflammatory activity | |
| KR100417243B1 (en) | Pharmaceutical composition comprising the extract of Phyllostachys nigra var. henonis having anti-inflammatory activity for the prevention and treatment of inflammatory disease | |
| KR20160098568A (en) | COMPOSITION COMPRISING EXTRACT OF Quamoclit angulata HAVING ANTI-INFLAMMATORY ACTIVITY | |
| KR20130087928A (en) | COMPOSITION COMPRISING AND HEALTHY FOOD LUTEOLIN 5-O-β-D-GLUCOPYRANOSIDE OR THE EXTRACT OF CIRSIUM MAACKII FOR PREVENTING OR TREATING INFLAMMATORY DISEASE | |
| KR101687774B1 (en) | COMPOSITION COMPRISING EXTRACT OF Ainsliaea apiculata HAVING ANTI-OXIDANT AND ANTI-INFLAMMATORY ACTIVITY | |
| KR102471026B1 (en) | Cosmetic composition containing Cyperus spp. extract for antiinflammation or skin whitening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |